Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Pathogens ; 11(8)2022 Aug 01.
Article in English | MEDLINE | ID: mdl-36014990

ABSTRACT

As of 15 June, there have been, globally, a total of 2103 laboratory-confirmed cases and one probable case of Monkeypox, including one death. We report two cases of vesicular infectious diseases, one of those is the first case of Monkeypox in the Campania Region. The report, therefore, highlights a recrudescent infection disease that could represent a challenge in differential diagnosis with other vesicular infectious diseases such as Varicella Zoster Virus, during a pandemic season that does not seem to end. Indeed, varicella should be carefullu considered in differential diagnosis according to its vesicular or pustular rash to have a prompt diagnosis and public health response in case of monkeypox infection.

2.
In Vivo ; 27(3): 377-82, 2013.
Article in English | MEDLINE | ID: mdl-23606694

ABSTRACT

BACKGROUND/AIM: The etiology of autism spectrum disorders (ASD) is unknown. The measles-mumps-rubella (MMR) vaccination has been in the past implicated in ASD pathogenesis. The aim of our study was to evaluate the rate of seropositivity and the levels of antibodies against MMR antigens in a cohort of children with ASD compared to control children. PATIENTS AND METHODS: In a cohort of children with ASD and same-age healthy controls, we measured levels and seropositivity of antibodies against MMR. RESULTS: A total of 60 children, 31 with ASD and 29 controls were enrolled. The seropositivity rate and levels of all the three antibodies were similar in cases and controls. CONCLUSION: Children with ASD have a similar level and seropositivity rate of antibodies against the MMR vaccine to same-age controls. As persistent infections are typically associated with high antibody levels, our results support the arguments against a role of MMR vaccination as a causal factor or co-factor in development of ASD.


Subject(s)
Child Development Disorders, Pervasive/immunology , Measles-Mumps-Rubella Vaccine/immunology , Measles/prevention & control , Mumps/prevention & control , Rubella/prevention & control , Antibodies, Viral/blood , Antibodies, Viral/immunology , Case-Control Studies , Child , Child Development Disorders, Pervasive/blood , Child, Preschool , Female , Humans , Infant , Male , Measles/immunology , Mumps/immunology , Rubella/immunology
SELECTION OF CITATIONS
SEARCH DETAIL